Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609226 · ClinicalTrials.gov registry record · Phase 3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
A Phase 3 study of Sickle Cell Disease and Thalassemia, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT06609226: Recruiting Phase 3 study of Sickle Cell Disease and Thalassemia, sponsored by Novo Nordisk A/S.
NCT06609226 is a Phase 3 study of Sickle Cell Disease and Thalassemia that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 480 participants, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06609226, a Phase 3 study of Sickle Cell Disease and Thalassemia, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.
Primary Outcome
Measured as number of events.
Conditions Studied
Interventions
- DRUG Etavopivat A
- DRUG Etavopivat B
- DRUG Etavopivat C
Study Locations (20)
California
- Children's Hospital Los Angeles - Endocrinology - Los Angeles
- Children's Hospital Los Angeles - Endocrinology - Los Angeles
- UCSF Oakland Benioff ChildHosp - Oakland
- UCSF Oakland Benioff ChildHosp - Oakland
- Children's Hosp Of Orange - Orange
- University Of California Irvine - Orange
Georgia
- Emory University School of Medicine - Atlanta
- Children's Healthcare Atlanta - Atlanta
- Center for Blood Disorders Augusta University - Augusta
Florida
- Foundation for Sickle Cell Disease Research - Hollywood
- Univ of Miami/SCCC - Miami
Alabama
- Univ of Alabama Birmingham - Birmingham
Arizona
- Phoenix Children's Hsptl - Phoenix
Connecticut
- University of Connecticut - Farmington
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Univer Of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2030-12-30 |
| Phase | Phase 3 |
What NCT06609226 shows while recruiting
NCT06609226 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (65% higher).
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Etavopivat A is the first listed.
NCT06609226 names 20 study sites across 12 states, led by California, Georgia, Florida.
Frequently Asked Questions
What is clinical trial NCT06609226 about?
NCT06609226 is a clinical study titled "A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia". Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking in...
What is the current status of trial NCT06609226?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2025-01-10. Estimated completion is 2030-12-30.
What conditions does trial NCT06609226 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Thalassemia.
What interventions are being tested in trial NCT06609226?
The interventions under investigation include: Etavopivat A (DRUG), Etavopivat B (DRUG), Etavopivat C (DRUG).
Who is sponsoring clinical trial NCT06609226?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609226 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06609226's enrollment target sits among peer trials
480 8th of 213 higher than 206 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RECRUITING · Phase 3
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
RECRUITING · Phase 3
-
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
RECRUITING · Phase 3
-
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI